BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.

BioSenic S.A.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Paul Segall

Judith Segall

Michael D West

Lineage Cell Therapeutics, Inc.

Relief Resources is a non-profit organization that provides mental health support and professional referrals to the international Jewish community, connecting individuals with vetted mental health professionals.

Relief Resources

BioSenic develops innovative treatments for autoimmune diseases, specifically an arsenic trioxide-based treatment and cell therapy products. The company self-describes its offerings as unique.

Metric
Company Name	BioSenic S.A.	Lineage Cell Therapeutics, Inc.	Relief Resources
Symbol	BIOS	LCTX
MSH ID	COM:BIOSENIC	COM:LINEAGECELL	ORG:RELIEFHELP
Market	STOCKS	STOCKS	PRIVATE
Sector	Healthcare	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Mental Healthcare Services
Country	BE	US	US
Stage			Series A
Employee Count	12	68
Website	biosenic.com	lineagecell.com	reliefhelp.org
LinkedIn		lineagecell
Founders

Metric
Market Cap	3.69M	180.52M
Enterprise Value
Monthly Web Traffic			22.15K
Web Traffic Growth			37.58
Valuation
Raised Capital			15M

Metric
Revenue		8.95M
Revenue (LTM)
Revenue (NTM)
Gross Profit		7.58M
EBITDA		-24.04M
Operating Income		-24.73M
Net Income		-21.49M
EPS		-0.12
Diluted EPS		-0.12
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.91
Operating Profit Margin		-2.77
EBITDA Margin		-2.69
Net Profit Margin		-2.41
Return on Equity		-0.31
Return on Assets		-0.21
Return on Capital Employed		-0.27

COM:BIOSENIC

BioSenic

Last Close

0.01

25/11 08:29

Market Cap

3.49M

Beta: -

Volume Today

33.80K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-7.64
P/B Ratio		2.62
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		28.94
EV Multiple		-7.37

Metric
Days Sales Outstanding		17.98
Days Payables Outstanding		1.72K
Days Inventory Outstanding
Operating Cycle		30.40
Cash Conversion Cycle		13.87
Asset Turnover		0.09

Metric
Operating Cash Flow		-28.57M
Free Cash Flow		-29.24M
Cash Flow to Debt		-5.71
Operating Cash Flow/Sales		-2.72
Free Cash Flow Yield		-0.18

Metric
Cash & Equivalents		35.44M
Accounts Receivable		-446K
Inventory
Goodwill		10.67M
Debt to Capitalization		0.04
Debt to Assets		0.03
Current Ratio		2.74
Quick Ratio		2.71

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.52
R&D to Revenue		1.81
SG&A to Revenue		1.98